<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VALACYCLOVIR HYDROCHLORIDE - valacyclovir hydrochlorideÂ tablet, film coatedÂ </strong><br>AvKARE, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use valacyclovir hydrochloride tablets safely and effectively. See full prescribing information for valacyclovir hydrochloride tablets.<br><br>VALACYCLOVIR hydrochloride tablets, film-coated for oral use <br>Initial U.S. Approval: 1995</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Warnings and Precautions, Central Nervous System Effects (<a href="#i4i_section_id_a19a43b7-1b97-457b-b87d-42fd380d0bec">5.3</a>) 3/2010 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Valacyclovir hydrochloride tablets are a nucleoside analogue DNA polymerase inhibitor indicated for: </p>
<p class="Highlighta"><span class="Underline">Adult Patients (<a href="#i4i_section_id_0140ec53-ab1c-449d-8619-9974f9575b0c">1.1</a>)</span> </p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span><ul>
<li>Treatment in immunocompetent patients (initial or recurrent episode)</li>
<li>Suppression in immunocompetent or HIV-infected patients</li>
<li>Reduction of transmission</li>
</ul>
</li>
<li><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span></li>
</ul>
<p class="Highlighta"><span class="Underline">Pediatric Patients (<a href="#i4i_section_id_bd0c85c0-9dcd-4cea-b1f8-0ede1c08506f">1.2</a>)</span> </p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span></li>
</ul>
<p class="Highlighta"><span class="Underline">Limitations of Use (<a href="#i4i_section_id_d45b3cfd-6f3b-47cd-bfbb-56091a5083d3">1.3</a>)</span> </p>
<ul><li>The efficacy and safety of valacyclovir hydrochloride tablets have not been established in immunocompromised patients other than for the suppression of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in HIV-infected patients.</li></ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<a name="id_9ab11033-7053-47a8-9b35-c96ce647cae5"></a><table>
<col>
<col>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule" align="center" colspan="2" valign="top">
<span class="Bold">Adult Dosage</span> (<a href="#i4i_section_id_97cd7dd4-1c19-44c1-bade-325dd72ba289">2.1</a>)</td></tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span></td>
<td class="Botrule Lrule" align="left" valign="top">2 grams every 12 hours for 1 day</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span></td>
<td class="Botrule Lrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Â Â Initial episode</td>
<td class="Botrule Lrule" align="left" valign="top">1 gram twice daily for 10 days</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Â Â Recurrent episodes</td>
<td class="Botrule Lrule" align="left" valign="top">500 mg twice daily for 3 days</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â Suppressive therapy</td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â Â Â Â Â Â Immunocompetent patients</td>
<td align="left" valign="top">1 gram once daily</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Alternate dose in patients with â‰¤ 9 recurrences/yr Â </td>
<td align="left" valign="top">500 mg once daily</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Â Â Â Â Â Â Â HIV-infected patients</td>
<td class="Botrule Lrule" align="left" valign="top">500 mg twice daily</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Â Â Reduction of transmission</td>
<td class="Botrule Lrule" align="left" valign="top">500 mg once daily</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span></td>
<td class="Botrule Lrule" align="left" valign="top">1 gram 3 times daily for 7 days</td>
</tr>
<tr><td class="Botrule" align="center" colspan="2" valign="top">
<span class="Bold">Pediatric Dosage</span> (<a href="#i4i_section_id_37ec0363-014e-4b60-81e4-c19164507a4a">2.2</a>)</td></tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span> (â‰¥ 12 years of age)</td>
<td class="Botrule Lrule" align="left" valign="top">2 grams every 12 hours for 1 day</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span> (2 to &lt; 18 years of age) </td>
<td class="Botrule" align="left" valign="top"> 20 mg/kg 3 times daily for 5 days; not to exceed 1 gram 3 times daily </td>
</tr>
</tbody>
</table>
<p class="Highlighta">Valacyclovir oral suspension (25 mg/mL or 50 mg/mL) can be prepared from valacyclovir hydrochloride tablets, 500 mg. (<a href="#i4i_section_id_79fe1040-06f7-4c53-aa5f-94ea0702f19c">2.3</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 500 mg (unscored), 1 gram (partially scored) (<a href="#i4i_dosage_form_strength_id_42aa8c96-fb9b-4f47-b7d7-3de3a2e04815">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to valacyclovir (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>), acyclovir, or any component of the formulation. (<a href="#i4i_contraindications_id_40ab33d9-7d5f-417c-bbb9-ec0d491e1133">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic thrombocytopenic purpura</span>/<span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">hemolytic uremic syndrome</span> (TTP/HUS): Has occurred in patients with advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span> and in allogenic bone marrow transplant and renal transplant patients receiving 8 grams per day of valacyclovir hydrochloride tablets in clinical trials. Discontinue treatment if clinical symptoms and laboratory findings consistent with TTP/HUS occur. (<a href="#i4i_section_id_598b6446-7a4c-4da1-9f4e-0e776da35b2b">5.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span>: May occur in elderly patients (with or without reduced renal function), patients with underlying <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> who receive higher than recommended doses of valacyclovir hydrochloride tablets for their level of renal function, patients who receive concomitant nephrotoxic drugs, or inadequately hydrated patients. Use with caution in elderly patients and reduce dosage in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (<a href="#i4i_section_id_8852d0d9-211f-4d62-9d33-7cf05f88c2b0">2.4</a>, <a href="#i4i_section_id_039e2d0b-d41b-465b-bb41-19b8c58a5f4d">5.2</a>)</li>
<li>Central nervous system adverse reactions (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, and <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>): May occur in both adult and pediatric patients (with or without reduced renal function) and in patients with underlying <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> who receive higher than recommended doses of valacyclovir hydrochloride tablets for their level of renal function. Elderly patients are more likely to have central nervous system adverse reactions. Use with caution in elderly patients and reduce dosage in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (<a href="#i4i_section_id_8852d0d9-211f-4d62-9d33-7cf05f88c2b0">2.4</a>, <a href="#i4i_section_id_a19a43b7-1b97-457b-b87d-42fd380d0bec">5.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul>
<li>The most common adverse reactions reported in at least one indication by &gt; 10% of adult patients treated with valacyclovir hydrochloride tablets and more commonly than in patients treated with placebo are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. (<a href="#i4i_section_id_c2f7d863-5ee5-4200-a20b-799120e9918e">6.1</a>)</li>
<li>The only adverse reaction occurring in &gt; 10% of pediatric patients &lt; 18 years of age was <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. (<a href="#i4i_section_id_11f47880-7216-4823-8838-c483bd33a398">6.2</a>)Â </li>
</ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact TEVA USA, PHARMACOVIGILANCE at 1-888-838-2872, X6351 or drug.safety@tevapharm.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div><div><div></div></div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 7/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Adult Patients</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Pediatric Patients</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Limitations of Use</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Adult Dosing Recommendations</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Pediatric Dosing Recommendations</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Extemporaneous Preparation of Oral Suspension</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic Thrombocytopenic Purpura</span>/<span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">Hemolytic Uremic Syndrome</span> (TTP/HUS)</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute Renal Failure</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Central Nervous System Effects</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience in Adult Patients</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Clinical Trials Experience in Pediatric Patients</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span>)</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span> Infections</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span></a></h2>
<h2><a href="#section-13.4" class="toc">14.4 <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Importance of Adequate Hydration</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span>)</a></h2>
<h2><a href="#section-15.3" class="toc">17.3 <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span></a></h2>
<h2><a href="#section-15.4" class="toc">17.4 <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span></a></h2>
<h2><a href="#section-15.5" class="toc">17.5 <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_3b3021ec-73c9-4e0d-8302-562d27fbe651"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0140ec53-ab1c-449d-8619-9974f9575b0c"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Adult Patients</h2>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span>):</span> Valacyclovir hydrochloride tablets are indicated for treatment of <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span>). The efficacy of valacyclovir hydrochloride tablets initiated after the development of clinical signs of a <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sore (e.g., <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papule</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicle</span>, or <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>) has not been established.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span>:</span><span class="Italics">Initial Episode:</span> Valacyclovir hydrochloride tablets are indicated for treatment of the initial episode of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in immunocompetent adults. The efficacy of treatment with valacyclovir hydrochloride tablets when initiated more than 72 hours after the onset of signs and symptoms has not been established.</p>
<p><span class="Italics">Recurrent Episodes:</span> Valacyclovir hydrochloride tablets are indicated for treatment of recurrent episodes of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in immunocompetent adults. The efficacy of treatment with valacyclovir hydrochloride tablets when initiated more than 24 hours after the onset of signs and symptoms has not been established.</p>
<p><span class="Italics">Suppressive Therapy:</span> Valacyclovir hydrochloride tablets are indicated for chronic suppressive therapy of recurrent episodes of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in immunocompetent and in HIV-infected adults. The efficacy and safety of valacyclovir hydrochloride tablets for the suppression of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> beyond 1 year in immunocompetent patients and beyond 6 months in HIV-infected patients have not been established.</p>
<p><span class="Italics">Reduction of Transmission:</span> Valacyclovir hydrochloride tablets are indicated for the reduction of transmission of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in immunocompetent adults. The efficacy of valacyclovir hydrochloride tablets for the reduction of transmission of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> beyond 8 months in discordant couples has not been established. The efficacy of valacyclovir hydrochloride tablets for the reduction of transmission of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in individuals with multiple partners and non-heterosexual couples has not been established. Safer sex practices should be used with suppressive therapy (see current Centers for Disease Control and Prevention [CDC] <span class="Italics"><span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">Sexually Transmitted Diseases</span> Treatment Guidelines</span>).</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span>:</span> Valacyclovir hydrochloride tablets are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> (<span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">shingles</span>) in immunocompetent adults. The efficacy of valacyclovir hydrochloride tablets when initiated more than 72 hours after the onset of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and the efficacy and safety of valacyclovir hydrochloride tablets for treatment of disseminated <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bd0c85c0-9dcd-4cea-b1f8-0ede1c08506f"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Pediatric Patients</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Â </span><span class="Underline"><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span>):</span> Valacyclovir hydrochloride tablets are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span>) in pediatric patients â‰¥ 12 years of age. The efficacy of valacyclovir hydrochloride tablets initiated after the development of clinical signs of a <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sore (e.g., <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papule</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicle</span>, or <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>) has not been established.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span>:</span> Valacyclovir hydrochloride tablets are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> in immunocompetent pediatric patients 2 to &lt; 18 years of age. Based on efficacy data from clinical studies with oral acyclovir, treatment with valacyclovir hydrochloride tablets should be initiated within 24 hours after the onset of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> [<span class="Italics">see Clinical Studies (<a href="#i4i_section_id_c5717931-afec-457b-a3e5-e0df9dca12ee">14.4</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d45b3cfd-6f3b-47cd-bfbb-56091a5083d3"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Limitations of Use</h2>
<p class="First">The efficacy and safety of valacyclovir hydrochloride tablets have not been established in:</p>
<ul>
<li>Immunocompromised patients other than for the suppression of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in HIV-infected patients with a CD4+ cell count â‰¥ 100 cells/mm<span class="Sup">3</span>.</li>
<li>Patients &lt; 12 years of age with <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span>).</li>
<li>Patients &lt; 2 years of age or â‰¥ 18 years of age with <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>.</li>
<li>Patients &lt; 18 years of age with <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>.</li>
<li>Patients &lt; 18 years of age with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>.</li>
<li>Neonates and infants as suppressive therapy following neonatal herpes simplex virus (HSV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_e96c8a6a-2565-4e30-a00d-f46bd3ce9448"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<ul>
<li>Valacyclovir hydrochloride tablets may be given without regard to meals.</li>
<li>Valacyclovir oral suspension (25 mg/mL or 50 mg/mL) may be prepared extemporaneously from valacyclovir hydrochloride tablets, 500 mg for use in pediatric patients for whom a solid dosage form is not appropriate [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_79fe1040-06f7-4c53-aa5f-94ea0702f19c">2.3</a>)</span>].</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_97cd7dd4-1c19-44c1-bade-325dd72ba289"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Adult Dosing Recommendations</h2>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span>):</span> The recommended dosage of valacyclovir hydrochloride tablets for treatment of <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> is 2 grams twice daily for 1 day taken 12 hours apart. Therapy should be initiated at the earliest symptom of a <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sore (e.g., <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, or burning).</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span>:</span><span class="Italics">Initial Episode:</span> The recommended dosage of valacyclovir hydrochloride tablets for treatment of initial <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> is 1 gram twice daily for 10 days. Therapy was most effective when administered within 48 hours of the onset of signs and symptoms.</p>
<p><span class="Italics">Recurrent Episodes:</span> The recommended dosage of valacyclovir hydrochloride tablets for treatment of recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> is 500 mg twice daily for 3 days. Initiate treatment at the first sign or symptom of an episode.</p>
<p><span class="Italics">Suppressive Therapy:</span> The recommended dosage of valacyclovir hydrochloride tablets for chronic suppressive therapy of recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> is 1 gram once daily in patients with normal immune function. In patients with a history of 9 or fewer recurrences per year, an alternative dose is 500 mg once daily.</p>
<p>In HIV-infected patients with a CD4+ cell count â‰¥ 100 cells/mm<span class="Sup">3</span>, the recommended dosage of valacyclovir hydrochloride tablets for chronic suppressive therapy of recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> is 500 mg twice daily.</p>
<p><span class="Italics">Reduction of Transmission:</span> The recommended dosage of valacyclovir hydrochloride tablets for reduction of transmission of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in patients with a history of 9 or fewer recurrences per year is 500 mg once daily for the source partner.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span>:</span> The recommended dosage of valacyclovir hydrochloride tablets for treatment of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> is 1 gram 3 times daily for 7 days. Therapy should be initiated at the earliest sign or symptom of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> and is most effective when started within 48 hours of the onset of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_37ec0363-014e-4b60-81e4-c19164507a4a"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Pediatric Dosing Recommendations</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Â </span><span class="Underline"><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span>):</span> The recommended dosage of valacyclovir hydrochloride tablets for the treatment of <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> in pediatric patients â‰¥ 12 years of age is 2 grams twice daily for 1 day taken 12 hours apart. Therapy should be initiated at the earliest symptom of a <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sore (e.g., <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, or burning).</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span>:</span> The recommended dosage of valacyclovir hydrochloride tablets for treatment of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> in immunocompetent pediatric patients 2 to &lt; 18 years of age is 20 mg/kg administered 3 times daily for 5 days. The total dose should not exceed 1 gram 3 times daily. Therapy should be initiated at the earliest sign or symptom [<span class="Italics">see Use in Specific Populations (<a href="#i4i_pediatric_use_id_adce7f29-896b-4ad6-ac38-1fdc092b5bad">8.4</a>), Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_a3ff2aa3-8920-40c2-82a4-3c78e8aedb01">12.3</a>), Clinical Studies (<a href="#i4i_section_id_c5717931-afec-457b-a3e5-e0df9dca12ee">14.4</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_79fe1040-06f7-4c53-aa5f-94ea0702f19c"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Extemporaneous Preparation of Oral Suspension</h2>
<p class="First"><span class="Underline">Ingredients and Preparation per USP-NF:</span> Valacyclovir hydrochloride tablets, 500 mg, cherry flavor, and Suspension Structured Vehicle USP-NF (SSV). Valacyclovir oral suspension (25 mg/mL or 50 mg/mL) should be prepared in lots of 100 mL. </p>
<p><span class="Underline">Prepare Suspension at Time of Dispensing as Follows:</span></p>
<ul>
<li>Prepare SSV according to the USP-NF. </li>
<li>Using a pestle and mortar, grind the required number of valacyclovir hydrochloride tablets, 500 mg until a fine powder is produced (5 valacyclovir hydrochloride tablets for 25 mg/mL suspension; 10 valacyclovir hydrochloride tablets for 50 mg/mL suspension). </li>
<li>Gradually add approximately 5 mL aliquots of SSV to the mortar and triturate the powder until a paste has been produced. Ensure that the powder has been adequately wetted. </li>
<li>Continue to add approximately 5 mL aliquots of SSV to the mortar, mixing thoroughly between additions, until a concentrated suspension is produced, to a minimum total quantity of 20 mL SSV and a maximum total quantity of 40 mL SSV for both the 25 mg/mL and 50 mg/mL suspensions. </li>
<li>Transfer the mixture to a suitable 100 mL measuring flask. </li>
<li>Transfer the cherry flavor* to the mortar and dissolve in approximately 5 mL of SSV. Once dissolved, add to the measuring flask. </li>
<li>Rinse the mortar at least 3 times with approximately 5 mL aliquots of SSV, transferring the rinsing to the measuring flask between additions. </li>
<li>Make the suspension to volume (100 mL) with SSV and shake thoroughly to mix. </li>
<li>Transfer the suspension to an amber glass medicine bottle with a child-resistant closure. </li>
<li>The prepared suspension should be labeled with the following information â€œShake well before using. Store suspension between 2Â° to 8Â°C (36Â° to 46Â°F) in a refrigerator. Discard after 28 days.â€? </li>
</ul>
<p>*The amount of cherry flavor added is as instructed by the suppliers of the cherry flavor.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8852d0d9-211f-4d62-9d33-7cf05f88c2b0"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Dosage recommendations for adult patients with reduced renal function are provided in <span class="Bold">Table 1</span> [<span class="Italics">see Use in Specific Populations (<a href="#i4i_geriatric_use_id_236259f5-af4f-4715-8efa-32135f95ce06">8.5</a>, <a href="#i4i_section_id_f1cc4501-4283-4717-8005-021d42b25d6d">8.6</a>), Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_a3ff2aa3-8920-40c2-82a4-3c78e8aedb01">12.3</a>)</span>]. Data are not available for the use of valacyclovir hydrochloride tablets in pediatric patients with a creatinine clearance &lt; 50 mL/min/1.73 m<span class="Sup">2</span>.</p>
<a name="id_43ea03c2-16ce-4ada-98bd-f024aa9bfbb2"></a><table width="429">
<caption><span>Table 1. Valacyclovir Hydrochloride Tablets Dosage Recommendations for Adults With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></caption>
<col width="27.7%">
<col width="20.3%">
<col width="18.2%">
<col width="18.2%">
<col width="15.6%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="left" rowspan="2" valign="bottom">Indications</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="bottom">Normal Dosage Regimen (Creatinine Clearance â‰¥ 50 mL/min)</td>
<td class="Botrule Lrule" align="center" colspan="3" valign="bottom">Creatinine Clearance (mL/min)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="bottom">30 to 49</td>
<td class="Botrule Rrule" align="center" valign="bottom">10 to 29</td>
<td class="Botrule Lrule" align="center" valign="bottom">&lt; 10</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes labialis</span>)</span></p>
<p><span class="Bold">Do not exceed 1 day of treatment.</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">Two 2 gram doses taken 12 hours apart</td>
<td class="Botrule Rrule" align="center" valign="top">Two 1 gram doses taken 12 hours apart</td>
<td class="Botrule Rrule" align="center" valign="top">Two 500 mg doses taken 12 hours apart</td>
<td class="Botrule Lrule" align="center" valign="top">500 mg single dose</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital herpes</span>:</span></p>
<p><span class="Bold">Â Â Â Initial episode</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">1 gram every 12 hours</td>
<td class="Botrule Rrule" align="center" valign="top">no reduction</td>
<td class="Botrule Rrule" align="center" valign="top">1 gram every 24 hours</td>
<td class="Botrule Lrule" align="center" valign="top">500 mg every 24 hours</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital herpes</span>:</span></p>
<p><span class="Bold">Â Â Â Recurrent episode</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">500 mg every 12 hours</td>
<td class="Botrule Rrule" align="center" valign="top">no reduction</td>
<td class="Botrule Rrule" align="center" valign="top">500 mg every 24 hours</td>
<td class="Botrule Lrule" align="center" valign="top">500 mg every 24 hours</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital herpes</span>:</span></p>
<p><span class="Bold">Â Â Â Suppressive therapy</span></p>
</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Immunocompetent patients</td>
<td class="Rrule" align="center" valign="top">1 gram every 24 hours</td>
<td class="Rrule" align="center" valign="top">no reduction</td>
<td class="Rrule" align="center" valign="top">500 mg every 24 hours</td>
<td align="center" valign="top">500 mg every 24 hours</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Alternate dose for immunocompetent patients with â‰¤ 9 recurrences/year</td>
<td class="Rrule" align="center" valign="top">500 mg every 24 hours</td>
<td class="Rrule" align="center" valign="top">no reduction</td>
<td class="Rrule" align="center" valign="top">500 mg every 48 hours</td>
<td align="center" valign="top">500 mg every 48 hours</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â HIV-infected patients</td>
<td class="Botrule Rrule" align="center" valign="top">500 mg every 12 hours</td>
<td class="Botrule Rrule" align="center" valign="top">no reduction</td>
<td class="Botrule Rrule" align="center" valign="top">500 mg every 24 hours</td>
<td class="Botrule Lrule" align="center" valign="top">500 mg every 24 hours</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes zoster</span></span></td>
<td class="Rrule" align="center" valign="top">1 gram every 8 hours</td>
<td class="Rrule" align="center" valign="top">1 gram every 12 hours</td>
<td class="Rrule" align="center" valign="top">1 gram every 24 hours</td>
<td class="Botrule" align="center" valign="top">500 mg every 24 hours</td>
</tr>
</tbody>
</table>
<p><span class="Underline">Hemodialysis:</span> Patients requiring hemodialysis should receive the recommended dose of valacyclovir hydrochloride tablets after hemodialysis. During hemodialysis, the half-life of acyclovir after administration of valacyclovir hydrochloride tablets is approximately 4 hours. About one third of acyclovir in the body is removed by dialysis during a 4 hour hemodialysis session.</p>
<p><span class="Underline">Peritoneal Dialysis:</span> There is no information specific to administration of valacyclovir hydrochloride tablets in patients receiving peritoneal dialysis. The effect of chronic ambulatory peritoneal dialysis (CAPD) and continuous arteriovenous hemofiltration/dialysis (CAVHD) on acyclovir pharmacokinetics has been studied. The removal of acyclovir after CAPD and CAVHD is less pronounced than with hemodialysis, and the pharmacokinetic parameters closely resemble those observed in patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (ESRD) not receiving hemodialysis. Therefore, supplemental doses of valacyclovir hydrochloride tablets should not be required following CAPD or CAVHD.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_42aa8c96-fb9b-4f47-b7d7-3de3a2e04815"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Tablets:</p>
<ul>
<li>500 mg: blue, film-coated, capsule-shaped tablet, debossed with "93" on one side and "7258" on the other</li>
<li>1 gram: blue, film-coated, capsule-shaped tablet, partially scored on both sides and debossed with "93" on one side and "7259" on the other</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_40ab33d9-7d5f-417c-bbb9-ec0d491e1133"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Valacyclovir hydrochloride tablets are contraindicated in patients who have had a demonstrated clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) to valacyclovir, acyclovir, or any component of the formulation [<span class="Italics">see Adverse Reactions (<a href="#i4i_section_id_e52aebbb-e8ae-4105-9630-38325c55cc67">6.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_f03861ea-83e0-4ae0-bf94-6060312457d4"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_598b6446-7a4c-4da1-9f4e-0e776da35b2b"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic Thrombocytopenic Purpura</span>/<span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">Hemolytic Uremic Syndrome</span> (TTP/HUS)</h2>
<p class="First">TTP/HUS, in some cases resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, has occurred in patients with advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span> and also in allogeneic bone marrow transplant and renal transplant recipients participating in clinical trials of valacyclovir hydrochloride tablets at doses of 8 grams per day. Treatment with valacyclovir hydrochloride tablets should be stopped immediately if clinical signs, symptoms, and laboratory abnormalities consistent with TTP/HUS occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_039e2d0b-d41b-465b-bb41-19b8c58a5f4d"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute Renal Failure</span></h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> have been reported in:</p>
<ul>
<li>Elderly patients with or without reduced renal function. Caution should be exercised when administering valacyclovir hydrochloride tablets to geriatric patients, and dosage reduction is recommended for those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_8852d0d9-211f-4d62-9d33-7cf05f88c2b0">2.4</a>), Use in Specific Populations (<a href="#i4i_geriatric_use_id_236259f5-af4f-4715-8efa-32135f95ce06">8.5</a>)</span>].</li>
<li>Patients with underlying <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> who received higher than recommended doses of valacyclovir hydrochloride tablets for their level of renal function. Dosage reduction is recommended when administering valacyclovir hydrochloride tablets to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_8852d0d9-211f-4d62-9d33-7cf05f88c2b0">2.4</a>), Use in Specific Populations (<a href="#i4i_section_id_f1cc4501-4283-4717-8005-021d42b25d6d">8.6</a>)</span>].</li>
<li>Patients receiving other nephrotoxic drugs. Caution should be exercised when administering valacyclovir hydrochloride tablets to patients receiving potentially nephrotoxic drugs.</li>
<li>Patients without adequate hydration. Precipitation of acyclovir in renal tubules may occur when the solubility (2.5 mg/mL) is exceeded in the intratubular fluid. Adequate hydration should be maintained for all patients.</li>
</ul>
<p>In the event of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, the patient may benefit from hemodialysis until renal function is restored [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_8852d0d9-211f-4d62-9d33-7cf05f88c2b0">2.4</a>), Adverse Reactions (<a href="#i4i_section_id_e52aebbb-e8ae-4105-9630-38325c55cc67">6.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a19a43b7-1b97-457b-b87d-42fd380d0bec"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Central Nervous System Effects</h2>
<p class="First" style="border-left:1px solid;">Central nervous system adverse reactions, including <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, have been reported in <span class="XmChange">both adult and pediatric</span> patients with or without reduced renal function and in patients with underlying <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> who received higher than recommended doses of valacyclovir hydrochloride tablets for their level of renal function. <span class="XmChange">Elderly patients are more likely to have central nervous system adverse reactions.</span> Valacyclovir hydrochloride tablets should be discontinued if central nervous system adverse reactions occur [<span class="Italics">see Adverse Reactions (<a href="#i4i_section_id_e52aebbb-e8ae-4105-9630-38325c55cc67">6.3</a>), Use in Specific Populations (<a href="#i4i_geriatric_use_id_236259f5-af4f-4715-8efa-32135f95ce06">8.5</a>, <a href="#i4i_section_id_f1cc4501-4283-4717-8005-021d42b25d6d">8.6</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_73cf0564-f191-4597-854b-34c417ba0a1b"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed in greater detail in other sections of the labeling:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic Thrombocytopenic Purpura</span>/<span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">Hemolytic Uremic Syndrome</span> [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_598b6446-7a4c-4da1-9f4e-0e776da35b2b">5.1</a>)</span>].</li>
<li><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute Renal Failure</span> [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_039e2d0b-d41b-465b-bb41-19b8c58a5f4d">5.2</a>)</span>].</li>
<li>Central Nervous System Effects [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_a19a43b7-1b97-457b-b87d-42fd380d0bec">5.3</a>)</span>].</li>
</ul>
<p>The most common adverse reactions reported in at least 1 indication by &gt; 10% of adult patients treated with valacyclovir hydrochloride tablets and observed more frequently with valacyclovir hydrochloride tablets compared to placebo are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. The only adverse reaction reported in &gt; 10% of pediatric patients &lt; 18 years of age was <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c2f7d863-5ee5-4200-a20b-799120e9918e"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience in Adult Patients</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span>):</span> In clinical studies for the treatment of <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span>, the adverse reactions reported by patients receiving valacyclovir hydrochloride tablets 2 grams twice daily (n = 609) or placebo (n = 609) for 1 day, respectively, included <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (14%, 10%) and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (2%, 1%). The frequencies of abnormal ALT (&gt; 2 x ULN) were 1.8% for patients receiving valacyclovir hydrochloride tablets compared with 0.8% for placebo. Other laboratory abnormalities (hemoglobin, white blood cells, alkaline phosphatase, and serum creatinine) occurred with similar frequencies in the 2 groups.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span>:</span><span class="Italics">Initial Episode:</span> In a clinical study for the treatment of initial episodes of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>, the adverse reactions reported by â‰¥ 5% of patients receiving valacyclovir hydrochloride tablets 1 gram twice daily for 10 days (n = 318) or oral acyclovir 200 mg 5 times daily for 10 days (n = 318), respectively, included <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (13%, 10%) and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (6%, 6%). For the incidence of laboratory abnormalities see <span class="Bold">Table 2</span>.</p>
<p><span class="Italics">Recurrent Episodes:</span> In 3 clinical studies for the episodic treatment of recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>, the adverse reactions reported by â‰¥ 5% of patients receiving valacyclovir hydrochloride tablets 500 mg twice daily for 3 days (n = 402), valacyclovir hydrochloride tablets 500 mg twice daily for 5 days (n = 1,136) or placebo (n = 259), respectively, included <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (16%, 11%, 14%) and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (5%, 4%, 5%). For the incidence of laboratory abnormalities see <span class="Bold">Table 2</span>.</p>
<p><span class="Italics">Suppressive Therapy: Suppression of Recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span> in Immunocompetent Adults:</span> In a clinical study for the suppression of recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> infections, the adverse reactions reported by patients receiving valacyclovir hydrochloride tablets 1 gram once daily (n = 269), valacyclovir hydrochloride tablets 500 mg once daily (n = 266), or placebo (n = 134), respectively, included <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (35%, 38%, 34%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (11%, 11%, 8%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (11%, 9%, 6%), <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span> (8%, 5%, 4%), <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (7%, 5%, 5%), <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> (6%, 5%, 4%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (3%, 3%, 2%), and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (4%, 2%, 1%). For the incidence of laboratory abnormalities see <span class="Bold">Table 2</span>.</p>
<p><span class="Italics">Suppression of Recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span> in HIV-Infected Patients:</span> In HIV-infected patients, frequently reported adverse reactions for valacyclovir hydrochloride tablets (500 mg twice daily; n = 194, median days on therapy = 172) and placebo (n = 99, median days on therapy = 59), respectively, included <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (13%, 8%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (8%, 5%), and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (8%, 1%). Post-randomization laboratory abnormalities that were reported more frequently in valacyclovir subjects versus placebo included elevated alkaline phosphatase (4%, 2%), elevated ALT (14%, 10%), elevated AST (16%, 11%), decreased neutrophil counts (18%, 10%), and decreased platelet counts (3%, 0%), respectively.</p>
<p><span class="Italics">Reduction of Transmission:</span> In a clinical study for the reduction of transmission of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>, the adverse reactions reported by patients receiving valacyclovir hydrochloride tablets 500 mg once daily (n = 743) or placebo once daily (n = 741), respectively, included <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (29%, 26%), <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span> (16%, 15%), and <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span> (9%, 10%).</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span>:</span> In 2 clinical studies for the treatment of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, the adverse reactions reported by patients receiving valacyclovir hydrochloride tablets 1 gram 3 times daily for 7 to 14 days (n = 967) or placebo (n = 195), respectively, included <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (15%, 8%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (14%, 12%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (6%, 3%), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (3%, 2%), and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (3%, 2%). For the incidence of laboratory abnormalities see <span class="Bold">Table 2</span>.</p>
<a name="id_da7bcd32-27c7-4838-a651-951b6f633b82"></a><table width="0.000">
<caption><span>Table 2. Incidence (%) of Laboratory Abnormalities in <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span> and <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span> Study Populations</span></caption>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<tfoot><tr><td colspan="9" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Data were not collected prospectively.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="left" rowspan="2" valign="bottom">Laboratory Abnormality</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span></td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top"><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span> Treatment</td>
<td class="Botrule Lrule" align="center" colspan="3" valign="top"><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span> Suppression</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top">Valacyclovir hydrochloride tablets 1 gram 3 times daily (n = 967)</td>
<td class="Botrule Rrule" align="center" valign="top">Placebo (n = 195)</td>
<td class="Botrule Rrule" align="center" valign="top">Valacyclovir hydrochloride tablets 1 gram twice daily (n = 1,194)</td>
<td class="Botrule Rrule" align="center" valign="top">Valacyclovir hydrochloride tablets 500 mg twice daily (n = 1,159)</td>
<td class="Botrule Rrule" align="center" valign="top">Placebo (n = 439)</td>
<td class="Botrule Rrule" align="center" valign="top">Valacyclovir hydrochloride tablets 1 gram once daily (n = 269)</td>
<td class="Botrule Rrule" align="center" valign="top">Valacyclovir hydrochloride tablets 500 mg once daily (n = 266)</td>
<td class="Botrule Lrule" align="center" valign="top">Placebo (n = 134)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Hemoglobin (&lt; 0.8 x LLN)</td>
<td class="Botrule Rrule" align="center" valign="top">0.8%</td>
<td class="Botrule Rrule" align="center" valign="top">0%</td>
<td class="Botrule Rrule" align="center" valign="top">0.3%</td>
<td class="Botrule Rrule" align="center" valign="top">0.2%</td>
<td class="Botrule Rrule" align="center" valign="top">0%</td>
<td class="Botrule Rrule" align="center" valign="top">0%</td>
<td class="Botrule Rrule" align="center" valign="top">0.8%</td>
<td class="Botrule Lrule" align="center" valign="top">0.8%</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">White blood cells (&lt; 0.75 x LLN)</td>
<td class="Botrule Rrule" align="center" valign="top">1.3%</td>
<td class="Botrule Rrule" align="center" valign="top">0.6%</td>
<td class="Botrule Rrule" align="center" valign="top">0.7%</td>
<td class="Botrule Rrule" align="center" valign="top">0.6%</td>
<td class="Botrule Rrule" align="center" valign="top">0.2%</td>
<td class="Botrule Rrule" align="center" valign="top">0.7%</td>
<td class="Botrule Rrule" align="center" valign="top">0.8%</td>
<td class="Botrule Lrule" align="center" valign="top">1.5%</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Platelet count (&lt; 100,000/mm<span class="Sup">3</span>)</td>
<td class="Botrule Rrule" align="center" valign="top">1.0%</td>
<td class="Botrule Rrule" align="center" valign="top">1.2%</td>
<td class="Botrule Rrule" align="center" valign="top">0.3%</td>
<td class="Botrule Rrule" align="center" valign="top">0.1%</td>
<td class="Botrule Rrule" align="center" valign="top">0.7%</td>
<td class="Botrule Rrule" align="center" valign="top">0.4%</td>
<td class="Botrule Rrule" align="center" valign="top">1.1%</td>
<td class="Botrule Lrule" align="center" valign="top">1.5%</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) (&gt; 2 x ULN)</td>
<td class="Botrule Rrule" align="center" valign="top">1.0%</td>
<td class="Botrule Rrule" align="center" valign="top">0%</td>
<td class="Botrule Rrule" align="center" valign="top">1.0%</td>
<td class="Botrule Rrule" align="center" valign="top"><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></td>
<td class="Botrule Rrule" align="center" valign="top">0.5%</td>
<td class="Botrule Rrule" align="center" valign="top">4.1%</td>
<td class="Botrule Rrule" align="center" valign="top">3.8%</td>
<td class="Botrule Lrule" align="center" valign="top">3.0%</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left" valign="top">Serum creatinine (&gt; 1.5 x ULN)</td>
<td class="Rrule" align="center" valign="top">0.2%</td>
<td class="Rrule" align="center" valign="top">0%</td>
<td class="Rrule" align="center" valign="top">0.7%</td>
<td class="Rrule" align="center" valign="top">0%</td>
<td class="Rrule" align="center" valign="top">0%</td>
<td class="Rrule" align="center" valign="top">0%</td>
<td class="Rrule" align="center" valign="top">0%</td>
<td class="Botrule" align="center" valign="top">0%</td>
</tr>
</tbody>
</table>
<p>LLN = Lower limit of normal.</p>
<p>ULN = Upper limit of normal.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_11f47880-7216-4823-8838-c483bd33a398"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Clinical Trials Experience in Pediatric Patients</h2>
<p class="First">The safety profile of valacyclovir hydrochloride tablets has been studied in 177 pediatric patients 1 month to &lt; 18 years of age. Sixty-five of these pediatric patients, 12 to &lt; 18 years of age, received oral caplets for 1 to 2 days for treatment of <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span>. The remaining 112 pediatric patients, 1 month to &lt; 12 years of age, participated in 3 pharmacokinetic and safety studies and received valacyclovir oral suspension. Fifty-one of these 112 pediatric patients received oral suspension for 3 to 6 days. The frequency, intensity, and nature of clinical adverse reactions and laboratory abnormalities were similar to those seen in adults. </p>
<p><span class="Underline">Pediatric Patients 12 to &lt; 18 Years of Age (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span>):</span> In clinical studies for the treatment of <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span>, the adverse reactions reported by adolescent patients receiving valacyclovir hydrochloride tablets 2 grams twice daily for 1 day, or valacyclovir hydrochloride tablets 2 grams twice daily for 1 day followed by 1 gram twice daily for 1 day (n = 65, across both dosing groups), or placebo (n = 30), respectively, included <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (17%, 3%) and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (8%, 0%). </p>
<p><span class="Underline">Pediatric Patients 1 Month to &lt; 12 Years of Age:</span> Adverse events reported in more than 1 subject across the 3 pharmacokinetic and safety studies in children 1 month to &lt; 12 years of age were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (5%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (4%), <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> (2%), herpes simplex (2%), and <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span> (2%). No clinically meaningful changes in laboratory values were observed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e52aebbb-e8ae-4105-9630-38325c55cc67"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Postmarketing Experience</h2>
<p class="First">In addition to adverse events reported from clinical trials, the following events have been identified during postmarketing use of valacyclovir hydrochloride tablets. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to valacyclovir hydrochloride tablets.</p>
<p><span class="Underline">General:</span> Facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</p>
<p><span class="Underline">Allergic:</span> Acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> [<span class="Italics">see Contraindications (<a href="#i4i_contraindications_id_40ab33d9-7d5f-417c-bbb9-ec0d491e1133">4</a>)</span>].</p>
<p><span class="Underline">CNS Symptoms:</span> <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggressive behavior</span>; <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>; <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>; <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>; <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>; decreased consciousness; <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>; <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>; <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>; and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, including auditory and <span class="product-label-link" type="condition" conceptid="4275889" conceptname="Visual hallucinations">visual hallucinations</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span> [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_a19a43b7-1b97-457b-b87d-42fd380d0bec">5.3</a>), Use in Specific Populations (<a href="#i4i_geriatric_use_id_236259f5-af4f-4715-8efa-32135f95ce06">8.5</a>), (<a href="#i4i_section_id_f1cc4501-4283-4717-8005-021d42b25d6d">8.6</a>)</span>].</p>
<p><span class="Underline">Eye:</span> Visual abnormalities.</p>
<p><span class="Underline">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>.</p>
<p><span class="Underline">Hepatobiliary Tract and Pancreas:</span> Liver enzyme abnormalities, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>.</p>
<p><span class="Underline">Renal:</span> <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span>, <span class="product-label-link" type="condition" conceptid="4167250" conceptname="Renal pain">renal pain</span> (may be associated with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>) [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_039e2d0b-d41b-465b-bb41-19b8c58a5f4d">5.2</a>), Use in Specific Populations (<a href="#i4i_geriatric_use_id_236259f5-af4f-4715-8efa-32135f95ce06">8.5</a>), (<a href="#i4i_section_id_f1cc4501-4283-4717-8005-021d42b25d6d">8.6</a>)</span>].</p>
<p><span class="Underline">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">leukocytoclastic vasculitis</span>, TTP/HUS [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_598b6446-7a4c-4da1-9f4e-0e776da35b2b">5.1</a>)</span>].</p>
<p><span class="Underline">Skin:</span> <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> including <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_edc870e5-dfe3-4df0-821c-d4ea34a0f501"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">No clinically significant drug-drug or drug-food interactions with valacyclovir hydrochloride tablets are known [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_a3ff2aa3-8920-40c2-82a4-3c78e8aedb01">12.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_2519bd90-bc56-4c55-9ca7-3bc024821e0b"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_1894e7d5-6c75-4bf7-afd2-6c08dbdc4011"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_e705a0a4-2760-4f52-bc68-c6e724fee31c"></a><a name="section-8.1.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_pregnancy_B_id_8687d81d-610c-4c43-a800-bd652edd3759"></a><a name="section-8.1.1.1"></a><p></p>
<h4>Pregnancy category B</h4>
<p class="First">There are no adequate and well-controlled studies of valacyclovir hydrochloride tablets or acyclovir in pregnant women. Based on prospective pregnancy registry data on 749 pregnancies, the overall rate of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in infants exposed to acyclovir <span class="Italics">in utero</span> appears similar to the rate for infants in the general population. Valacyclovir hydrochloride tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>A prospective epidemiologic registry of acyclovir use during pregnancy was established in 1984 and completed in April 1999. There were 749 pregnancies followed in women exposed to systemic acyclovir during the first trimester of pregnancy resulting in 756 outcomes. The occurrence rate of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> approximates that found in the general population. However, the small size of the registry is insufficient to evaluate the risk for less common defects or to permit reliable or definitive conclusions regarding the safety of acyclovir in pregnant women and their developing fetuses.</p>
<p>Animal reproduction studies performed at oral doses that provided up to 10 and 7 times the human plasma levels during the period of major organogenesis in rats and rabbits, respectively, revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_7314ed07-dcc0-48a9-a9f4-a74fa31ce339"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Following oral administration of a 500 mg dose of valacyclovir hydrochloride tablets to 5 nursing mothers, peak acyclovir concentrations (C<span class="Sub">max</span>) in breast milk ranged from 0.5 to 2.3 times (median 1.4) the corresponding maternal acyclovir serum concentrations. The acyclovir breast milk AUC ranged from 1.4 to 2.6 times (median 2.2) maternal serum AUC. A 500 mg maternal dosage of valacyclovir hydrochloride tablets twice daily would provide a nursing infant with an oral acyclovir dosage of approximately 0.6 mg/kg/day. This would result in less than 2% of the exposure obtained after administration of a standard neonatal dose of 30 mg/kg/day of intravenous acyclovir to the nursing infant. Unchanged valacyclovir was not detected in maternal serum, breast milk, or infant urine. Caution should be exercised when valacyclovir hydrochloride tablets are administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_adce7f29-896b-4ad6-ac38-1fdc092b5bad"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Valacyclovir hydrochloride tablets are indicated for treatment of <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> in pediatric patients â‰¥ 12 years of age and for treatment of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> in pediatric patients 2 to &lt; 18 years of age [<span class="Italics">see Indications and Usage (<a href="#i4i_section_id_bd0c85c0-9dcd-4cea-b1f8-0ede1c08506f">1.2</a>), Dosage and Administration (<a href="#i4i_section_id_37ec0363-014e-4b60-81e4-c19164507a4a">2.2</a>)</span>].</p>
<p>The use of valacyclovir hydrochloride tablets for treatment of <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> is based on 2 double-blind, placebo-controlled clinical trials in healthy adults and adolescents (â‰¥ 12 years of age) with a history of recurrent <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> [<span class="Italics">see Clinical Studies (<a href="#i4i_section_id_ca7d5a22-38a1-4482-9a95-ca6627444d8d">14.1</a>)</span>].</p>
<p>The use of valacyclovir hydrochloride tablets for treatment of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> in pediatric patients 2 to &lt; 18 years of age is based on single-dose pharmacokinetic and multiple-dose safety data from an open-label trial with valacyclovir and supported by efficacy and safety data from 3 randomized, double-blind, placebo-controlled trials evaluating oral acyclovir in pediatric patients with <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_37ec0363-014e-4b60-81e4-c19164507a4a">2.2</a>), Adverse Reactions (<a href="#i4i_section_id_11f47880-7216-4823-8838-c483bd33a398">6.2</a>), Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_a3ff2aa3-8920-40c2-82a4-3c78e8aedb01">12.3</a>), Clinical Studies (<a href="#i4i_section_id_c5717931-afec-457b-a3e5-e0df9dca12ee">14.4</a>)</span>].</p>
<p>The efficacy and safety of valacyclovir have not been established in pediatric patients:</p>
<ul>
<li>&lt; 12 years of age with <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span></li>
<li>&lt; 18 years of age with <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span></li>
<li>&lt; 18 years of age with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span></li>
<li>&lt; 2 years of age with <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> </li>
<li>for suppressive therapy following neonatal HSV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</li>
</ul>
<p>The pharmacokinetic profile and safety of valacyclovir oral suspension in children &lt; 12 years of age were studied in 3 open-label studies. No efficacy evaluations were conducted in any of the 3 studies. </p>
<p>Study 1 was a single-dose pharmacokinetic, multiple-dose safety study in 27 pediatric patients 1 to &lt; 12 years of age with clinically suspected <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>-zoster virus (VZV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_37ec0363-014e-4b60-81e4-c19164507a4a">2.2</a>), Adverse Reactions (<a href="#i4i_section_id_11f47880-7216-4823-8838-c483bd33a398">6.2</a>), Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_a3ff2aa3-8920-40c2-82a4-3c78e8aedb01">12.3</a>), Clinical Studies (<a href="#i4i_section_id_c5717931-afec-457b-a3e5-e0df9dca12ee">14.4</a>)</span>]. </p>
<p>Study 2 was a single-dose pharmacokinetic and safety study in pediatric patients 1 month to &lt; 6 years of age who had an active <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes virus infection</span> or who were at risk for <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes virus infection</span>. Fifty-seven subjects were enrolled and received a single dose of 25 mg/kg valacyclovir oral suspension. In infants and children 3 months to &lt; 6 years of age, this dose provided comparable systemic acyclovir exposures to that from a 1 gram dose of valacyclovir in adults (historical data). In infants 1 month to &lt; 3 months of age, mean acyclovir exposures resulting from a 25 mg/kg dose were higher (C<span class="Sub">max</span>: â†‘30%, AUC: â†‘60%) than acyclovir exposures following a 1 gram dose of valacyclovir in adults. Acyclovir is not approved for suppressive therapy in infants and children following neonatal HSV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>; therefore valacyclovir is not recommended for this indication because efficacy cannot be extrapolated from acyclovir. </p>
<p>Study 3 was a single-dose pharmacokinetic, multiple-dose safety study in 28 pediatric patients 1 to &lt; 12 years of age with clinically suspected HSV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. None of the children enrolled in this study had <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>. Each subject was dosed with valacyclovir oral suspension, 10 mg/kg twice daily for 3 to 5 days. Acyclovir systemic exposures in pediatric patients following valacyclovir oral suspension were compared with historical acyclovir systemic exposures in immunocompetent adults receiving the solid oral dosage form of valacyclovir or acyclovir for the treatment of recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>. The mean projected daily acyclovir systemic exposures in pediatric patients across all age-groups (1 to &lt; 12 years of age) were lower (C<span class="Sub">max</span>: â†“20%, AUC: â†“33%) compared with the acyclovir systemic exposures in adults receiving valacyclovir 500 mg twice daily, but were higher (daily AUC: â†‘16%) than systemic exposures in adults receiving acyclovir 200 mg 5 times daily. Insufficient data are available to support valacyclovir for the treatment of recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in this age-group because clinical information on recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in young children is limited; therefore, extrapolating efficacy data from adults to this population is not possible. Moreover, valacyclovir has not been studied in children 1 to &lt; 12 years of age with recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_236259f5-af4f-4715-8efa-32135f95ce06"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total number of subjects in clinical studies of valacyclovir hydrochloride tablets, 906 were 65 and over, and 352 were 75 and over. In a clinical study of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, the duration of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> after healing (post-herpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>) was longer in patients 65 and older compared with younger adults. Elderly patients are more likely to have reduced renal function and require dose reduction. Elderly patients are also more likely to have renal or CNS adverse events [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_8852d0d9-211f-4d62-9d33-7cf05f88c2b0">2.4</a>), Warnings and Precautions (<a href="#i4i_section_id_039e2d0b-d41b-465b-bb41-19b8c58a5f4d">5.2</a>, <a href="#i4i_section_id_a19a43b7-1b97-457b-b87d-42fd380d0bec">5.3</a>), Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_a3ff2aa3-8920-40c2-82a4-3c78e8aedb01">12.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f1cc4501-4283-4717-8005-021d42b25d6d"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Dosage reduction is recommended when administering valacyclovir hydrochloride tablets to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_8852d0d9-211f-4d62-9d33-7cf05f88c2b0">2.4</a>), Warnings and Precautions (<a href="#i4i_section_id_039e2d0b-d41b-465b-bb41-19b8c58a5f4d">5.2</a>, <a href="#i4i_section_id_a19a43b7-1b97-457b-b87d-42fd380d0bec">5.3</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_540c857e-021e-4bc9-b62a-e83541650ee7"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Caution should be exercised to prevent inadvertent <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> [<span class="Italics">see Use in Specific Populations (<a href="#i4i_geriatric_use_id_236259f5-af4f-4715-8efa-32135f95ce06">8.5</a>), (<a href="#i4i_section_id_f1cc4501-4283-4717-8005-021d42b25d6d">8.6</a>)</span>]. Precipitation of acyclovir in renal tubules may occur when the solubility (2.5 mg/mL) is exceeded in the intratubular fluid. In the event of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, the patient may benefit from hemodialysis until renal function is restored [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_8852d0d9-211f-4d62-9d33-7cf05f88c2b0">2.4</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_f0a6ab7b-9849-4328-9bac-7c2b6ab583e0"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Valacyclovir hydrochloride is the hydrochloride salt of the <span class="Italics">L</span>-valyl ester of the antiviral drug acyclovir.</p>
<p>Valacyclovir hydrochloride tablets are for oral administration. Each tablet contains valacyclovir hydrochloride equivalent to 500 mg or 1 gram valacyclovir and the inactive ingredients cellulose, croscarmellose sodium, FD&amp;C blue #2, hypromellose, maize starch, polyethylene glycol, polysorbate 80, sodium stearyl fumarate, and titanium dioxide.</p>
<p>The chemical name of valacyclovir hydrochloride is <span class="Italics">L</span>-valine, 2-[(2-amino-1,6-dihydro-6-oxo-9<span class="Italics">H</span>-purin-9-yl)methoxy]ethyl ester, monohydrochloride. It has the following structural formula: </p>
<div class="Figure"><img alt="valacyclovir hydrochloride structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c31fdda3-217c-c452-eb9b-aba705456aa1&amp;name=e4c8e33d-80c8-4764-86bc-6689234d12f4-01.jpg"></div>
<p>C<span class="Sub">13</span>H<span class="Sub">20</span>N<span class="Sub">6</span>O<span class="Sub">4</span>â€¢HClÂ Â Â Â Â Â Â Â Â Â M.W. 360.80</p>
<p>Valacyclovir hydrochloride is a white to off-white powder. The maximum solubility in water at 25Â°C is 174 mg/mL. The pk<span class="Sub">a</span>s for valacyclovir hydrochloride are 1.90, 7.47, and 9.43.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_0078c202-2a0a-43f8-9e8a-309d38443e06"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_b4afe347-c395-47bb-8431-f4f8a15f1c90"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Valacyclovir is an antiviral drug [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_microbiology_id_7aa07a48-e152-40db-be97-e103ab345847">12.4</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_a3ff2aa3-8920-40c2-82a4-3c78e8aedb01"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of valacyclovir and acyclovir after oral administration of valacyclovir hydrochloride tablets have been investigated in 14 volunteer studies involving 283 adults and in 3 studies involving 112 pediatric subjects from 1 month to &lt; 12 years of age.</p>
<p><span class="Underline">Pharmacokinetics in Adults:</span><span class="Italics">Absorption and Bioavailability:</span> After oral administration, valacyclovir hydrochloride is rapidly absorbed from the gastrointestinal tract and nearly completely converted to acyclovir and <span class="Italics">L</span>-valine by first-pass intestinal and/or hepatic metabolism.</p>
<p>The absolute bioavailability of acyclovir after administration of valacyclovir hydrochloride tablets is 54.5% Â± 9.1% as determined following a 1 gram oral dose of valacyclovir hydrochloride tablets and a 350 mg intravenous acyclovir dose to 12 healthy volunteers. Acyclovir bioavailability from the administration of valacyclovir hydrochloride tablets is not altered by administration with food (30 minutes after an 873 Kcal breakfast, which included 51 grams of fat).</p>
<p>Acyclovir pharmacokinetic parameter estimates following administration of valacyclovir hydrochloride tablets to healthy adult volunteers are presented in <span class="Bold">Table 3</span>. There was a less than dose-proportional increase in acyclovir maximum concentration (C<span class="Sub">max</span>) and area under the acyclovir concentration-time curve (AUC) after single-dose and multiple-dose administration (4 times daily) of valacyclovir hydrochloride tablets from doses between 250 mg to 1 gram.</p>
<p>There is no accumulation of acyclovir after the administration of valacyclovir at the recommended dosage regimens in adults with normal renal function.</p>
<a name="id_0429ff65-bc95-4c4b-85cc-6e06f38b4fef"></a><table width="0.000">
<caption><span>Table 3. Mean (Â± SD) Plasma Acyclovir Pharmacokinetic Parameters Following Administration of Valacyclovir Hydrochloride Tablets to Healthy Adult Volunteers</span></caption>
<col>
<col>
<col>
<col>
<col>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Administered 4 times daily for 11 days.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="left" rowspan="2" valign="top">Dose</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">
<p class="First">Single-Dose Administration</p>
<p>(N = 8)</p>
</td>
<td class="Botrule Lrule" align="center" colspan="2" valign="top">
<p class="First">Multiple-Dose Administration<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></p>
<p>(N = 24, 8 per treatment arm)</p>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">C<span class="Sub">max</span> (Â± SD)</p>
<p>(mcg/mL)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">AUC (Â± SD)</p>
<p>(hrâ€¢mcg/mL)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">C<span class="Sub">max</span> (Â± SD)</p>
<p>(mcg/mL)</p>
</td>
<td class="Botrule Lrule" align="center" valign="top">
<p class="First">AUC (Â± SD)</p>
<p>(hrâ€¢mcg/mL)</p>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">100 mg</td>
<td class="Botrule Rrule" align="center" valign="top">0.83 (Â± 0.14)</td>
<td class="Botrule Rrule" align="center" valign="top">2.28 (Â± 0.40)</td>
<td class="Botrule Rrule" align="center" valign="top">ND</td>
<td class="Botrule Lrule" align="center" valign="top">ND</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">250 mg</td>
<td class="Botrule Rrule" align="center" valign="top">2.15 (Â± 0.50)</td>
<td class="Botrule Rrule" align="center" valign="top">5.76 (Â± 0.60)</td>
<td class="Botrule Rrule" align="center" valign="top">2.11 (Â± 0.33)</td>
<td class="Botrule Lrule" align="center" valign="top">5.66 (Â± 1.09)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">500 mg</td>
<td class="Botrule Rrule" align="center" valign="top">3.28 (Â± 0.83)</td>
<td class="Botrule Rrule" align="center" valign="top">11.59 (Â± 1.79)</td>
<td class="Botrule Rrule" align="center" valign="top">3.69 (Â± 0.87)</td>
<td class="Botrule Lrule" align="center" valign="top">9.88 (Â± 2.01)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">750 mg</td>
<td class="Botrule Rrule" align="center" valign="top">4.17 (Â± 1.14)</td>
<td class="Botrule Rrule" align="center" valign="top">14.11 (Â± 3.54)</td>
<td class="Botrule Rrule" align="center" valign="top">ND</td>
<td class="Botrule Lrule" align="center" valign="top">ND</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left" valign="top">1,000 mg</td>
<td class="Rrule" align="center" valign="top">5.65 (Â± 2.37)</td>
<td class="Rrule" align="center" valign="top">19.52 (Â± 6.04)</td>
<td class="Rrule" align="center" valign="top">4.96 (Â± 0.64)</td>
<td class="Botrule" align="center" valign="top">15.70 (Â± 2.27)</td>
</tr>
</tbody>
</table>
<p>ND = not done.</p>
<p><span class="Italics">Distribution:</span> The binding of valacyclovir to human plasma proteins ranges from 13.5% to 17.9%. The binding of acyclovir to human plasma proteins ranges from 9% to 33%.</p>
<p><span class="Italics">Metabolism:</span> Valacyclovir is converted to acyclovir and <span class="Italics">L</span>-valine by first-pass intestinal and/or hepatic metabolism. Acyclovir is converted to a small extent to inactive metabolites by aldehyde oxidase and by alcohol and aldehyde dehydrogenase. Neither valacyclovir nor acyclovir is metabolized by cytochrome P450 enzymes. Plasma concentrations of unconverted valacyclovir are low and transient, generally becoming non-quantifiable by 3 hours after administration. Peak plasma valacyclovir concentrations are generally less than 0.5 mcg/mL at all doses. After single-dose administration of 1 gram of valacyclovir hydrochloride tablets, average plasma valacyclovir concentrations observed were 0.5, 0.4, and 0.8 mcg/mL in patients with hepatic dysfunction, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, and in healthy volunteers who received concomitant cimetidine and probenecid, respectively.</p>
<p><span class="Italics">Elimination:</span> The pharmacokinetic disposition of acyclovir delivered by valacyclovir is consistent with previous experience from intravenous and oral acyclovir. Following the oral administration of a single 1 gram dose of radiolabeled valacyclovir to 4 healthy subjects, 46% and 47% of administered radioactivity was recovered in urine and feces, respectively, over 96 hours. Acyclovir accounted for 89% of the radioactivity excreted in the urine. Renal clearance of acyclovir following the administration of a single 1 gram dose of valacyclovir hydrochloride tablets to 12 healthy volunteers was approximately 255 Â± 86 mL/min which represents 42% of total acyclovir apparent plasma clearance.</p>
<p>The plasma elimination half-life of acyclovir typically averaged 2.5 to 3.3 hours in all studies of valacyclovir hydrochloride tablets in volunteers with normal renal function.</p>
<p><span class="Underline">Specific Populations:</span><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> Reduction in dosage is recommended in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_8852d0d9-211f-4d62-9d33-7cf05f88c2b0">2.4</a>), Use in Specific Populations (<a href="#i4i_geriatric_use_id_236259f5-af4f-4715-8efa-32135f95ce06">8.5</a>), (<a href="#i4i_section_id_f1cc4501-4283-4717-8005-021d42b25d6d">8.6</a>)</span>].</p>
<p>Following administration of valacyclovir hydrochloride tablets to volunteers with ESRD, the average acyclovir half-life is approximately 14 hours. During hemodialysis, the acyclovir half-life is approximately 4 hours. Approximately one third of acyclovir in the body is removed by dialysis during a 4 hour hemodialysis session. Apparent plasma clearance of acyclovir in dialysis patients was 86.3 Â± 21.3 mL/min/1.73 m<span class="Sup">2</span> compared with 679.16 Â± 162.76 mL/min/1.73 m<span class="Sup">2</span> in healthy volunteers.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> Administration of valacyclovir hydrochloride tablets to patients with moderate (biopsy-proven cirrhosis) or severe (with and without <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span> and biopsy-proven cirrhosis) liver disease indicated that the rate but not the extent of conversion of valacyclovir to acyclovir is reduced, and the acyclovir half-life is not affected. Dosage modification is not recommended for patients with cirrhosis.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV Disease</span>:</span> In 9 patients with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span> and CD4+ cell counts &lt; 150 cells/mm<span class="Sup">3</span> who received valacyclovir hydrochloride tablets at a dosage of 1 gram 4 times daily for 30 days, the pharmacokinetics of valacyclovir  and acyclovir were not different from that observed in healthy volunteers.</p>
<p><span class="Italics">Geriatrics:</span> After single-dose administration of 1 gram of valacyclovir hydrochloride tablets in healthy geriatric volunteers, the half-life of acyclovir was 3.11 Â± 0.51 hours, compared with 2.91 Â± 0.63 hours in healthy younger adult volunteers. The pharmacokinetics of acyclovir following single- and multiple-dose oral administration of valacyclovir hydrochloride tablets in geriatric volunteers varied with renal function. Dose reduction may be required in geriatric patients, depending on the underlying renal status of the patient [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_8852d0d9-211f-4d62-9d33-7cf05f88c2b0">2.4</a>), Use in Specific Populations (<a href="#i4i_geriatric_use_id_236259f5-af4f-4715-8efa-32135f95ce06">8.5</a>), (<a href="#i4i_section_id_f1cc4501-4283-4717-8005-021d42b25d6d">8.6</a>)</span>].</p>
<p><span class="Italics">Pediatrics:</span> Acyclovir pharmacokinetics have been evaluated in a total of 98 pediatric patients (1 month to &lt; 12 years of age) following administration of the first dose of an extemporaneous oral suspension of valacyclovir [<span class="Italics">see Adverse Reactions (<a href="#i4i_section_id_11f47880-7216-4823-8838-c483bd33a398">6.2</a>), Use in Specific Populations (<a href="#i4i_pediatric_use_id_adce7f29-896b-4ad6-ac38-1fdc092b5bad">8.4</a>)</span>]. Acyclovir pharmacokinetic parameter estimates following a 20 mg/kg dose are provided in <span class="Bold">Table 4</span>.</p>
<a name="id_8d4583da-2d61-4110-9c75-9c1be23f9146"></a><table border="single" width="504">
<caption><span>Table 4. Mean (Â± SD) Plasma Acyclovir Pharmacokinetic Parameter Estimates Following First-Dose Administration of 20 mg/kg Valacyclovir Oral Suspension to Pediatric Patients vs. 1 Gram Single Dose of Valacyclovir Hydrochloride Tablets to Adults</span></caption>
<col width="21.4%">
<col width="17.9%">
<col width="17.9%">
<col width="17.9%">
<col width="25.0%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Historical estimates using pediatric pharmacokinetic sampling schedule.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"></td>
<td class="Botrule Rrule" align="justify" colspan="3" valign="top"><p class="First">Pediatric Patients (20 mg/kg Oral Suspension)</p></td>
<td class="Botrule Rrule" align="center" rowspan="3" valign="top">
<p class="First">Adults</p>
<p>1 gram Solid Dose of Valacyclovir Hydrochloride Tablets<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></p>(N = 15)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="top">
<p class="First">1 to &lt; 2 yr</p>(N = 6)</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">
<p class="First">2 to &lt; 6 yr</p>(N = 12)</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="bottom">
<p class="First">6 to &lt; 12 yr</p>(N = 8)</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" valign="top">Parameter</td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">AUC (mcgâ€¢hr/mL) C<span class="Sub">max</span> (mcg/mL)</td>
<td class="Rrule" align="center" valign="top">
<p class="First">14.4 (Â± 6.26)</p>4.03 (Â± 1.37)</td>
<td class="Rrule" align="center" valign="top">
<p class="First">10.1 (Â± 3.35)</p>3.75 (Â± 1.14)</td>
<td class="Rrule" align="center" valign="top">
<p class="First">13.1 (Â± 3.43)</p>4.71 (Â± 1.20)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">17.2 (Â± 3.10)</p>4.72 (Â± 1.37)</td>
</tr>
</tbody>
</table>
<p><span class="Underline">Drug Interactions:</span> When valacyclovir hydrochloride tablets are coadministered with antacids, cimetidine and/or probenicid, digoxin, or thiazide diuretics in patients with normal renal function, the effects are not considered to be of clinical significance (see below). Therefore, when valacyclovir hydrochloride tablets are coadministered with these drugs in patients with normal renal function, no dosage adjustment is recommended.</p>
<p><span class="Italics">Antacids:</span> The pharmacokinetics of acyclovir after a single dose of valacyclovir hydrochloride tablets (1 gram) were unchanged by coadministration of a single dose of antacids (Al<span class="Sup">3+</span> or Mg<span class="Sup">++</span>).</p>
<p><span class="Italics">Cimetidine:</span> Acyclovir C<span class="Sub">max</span> and AUC following a single dose of valacyclovir hydrochloride tablets (1 gram) increased by 8% and 32%, respectively, after a single dose of cimetidine (800 mg).</p>
<p><span class="Italics">Cimetidine Plus Probenecid:</span> Acyclovir C<span class="Sub">max</span> and AUC following a single dose of valacyclovir hydrochloride tablets (1 gram) increased by 30% and 78%, respectively, after a combination of cimetidine and probenecid, primarily due to a reduction in renal clearance of acyclovir.</p>
<p><span class="Italics">Digoxin:</span> The pharmacokinetics of digoxin were not affected by coadministration of valacyclovir hydrochloride tablets 1 gram 3 times daily, and the pharmacokinetics of acyclovir after a single dose of valacyclovir hydrochloride tablets (1 gram) was unchanged by coadministration of digoxin (2 doses of 0.75 mg).</p>
<p><span class="Italics">Probenecid:</span> Acyclovir C<span class="Sub">max</span> and AUC following a single dose of valacyclovir hydrochloride tablets (1 gram) increased by 22% and 49%, respectively, after probenecid (1 gram).</p>
<p><span class="Italics">Thiazide Diuretics:</span> The pharmacokinetics of acyclovir after a single dose of valacyclovir hydrochloride tablets (1 gram) were unchanged by coadministration of multiple doses of thiazide diuretics.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="i4i_microbiology_id_7aa07a48-e152-40db-be97-e103ab345847"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First"><span class="Underline">Mechanism of Action:</span> Valacyclovir is a nucleoside analogue DNA polymerase inhibitor. Valacyclovir hydrochloride is rapidly converted to acyclovir which has demonstrated antiviral activity against HSV types 1 (HSV-1) and 2 (HSV-2) and VZV both in cell culture and <span class="Italics">in vivo</span>.</p>
<p>The inhibitory activity of acyclovir is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV. This viral enzyme converts acyclovir into acyclovir monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. In biochemical assays, acyclovir triphosphate inhibits replication of herpes viral DNA. This is accomplished in 3 ways: 1) competitive inhibition of viral DNA polymerase, 2) incorporation and termination of the growing viral DNA chain, and 3) inactivation of the viral DNA polymerase. The greater antiviral activity of acyclovir against HSV compared with VZV is due to its more efficient phosphorylation by the viral TK.</p>
<p><span class="Underline">Antiviral Activities:</span> The quantitative relationship between the cell culture susceptibility of herpes viruses to antivirals and the clinical response to therapy has not been established in humans, and virus sensitivity testing has not been standardized. Sensitivity testing results, expressed as the concentration of drug required to inhibit by 50% the growth of virus in cell culture (EC<span class="Sub">50</span>), vary greatly depending upon a number of factors. Using plaque-reduction assays, the EC<span class="Sub">50</span> values against herpes simplex virus isolates range from 0.09 to 60 ÂµM (0.02 to 13.5 mcg/mL) for HSV-1 and from 0.04 to 44 ÂµM (0.01 to 9.9 mcg/mL) for HSV-2. The EC<span class="Sub">50</span> values for acyclovir against most laboratory <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> and clinical isolates of VZV range from 0.53 to 48 ÂµM (0.12 to 10.8 mcg/mL). Acyclovir also demonstrates activity against the Oka vaccine <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of VZV with a mean EC<span class="Sub">50</span> of 6 ÂµM (1.35 mcg/mL).</p>
<p><span class="Underline">Resistance:</span> Resistance of HSV and VZV to acyclovir can result from qualitative and quantitative changes in the viral TK and/or DNA polymerase. Clinical isolates of VZV with reduced susceptibility to acyclovir have been recovered from patients with AIDS. In these cases, TK-deficient mutants of VZV have been recovered.</p>
<p>Resistance of HSV and VZV to acyclovir occurs by the same mechanisms. While most of the acyclovir-resistant mutants isolated thus far from immunocompromised patients have been found to be TK-deficient mutants, other mutants involving the viral TK gene (TK partial and TK altered) and DNA polymerase have also been isolated. TK-negative mutants may cause severe disease in immunocompromised patients. The possibility of viral resistance to valacyclovir (and therefore, to acyclovir) should be considered in patients who show poor clinical response during therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_62956d0d-057e-4e7f-a9cb-402bf0e79476"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_386f0f58-7e48-4c8b-9d4f-627ffc096855"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">The data presented below include references to the steady-state acyclovir AUC observed in humans treated with 1 gram valacyclovir hydrochloride tablets given orally 3 times a day to treat <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>. Plasma drug concentrations in animal studies are expressed as multiples of human exposure to acyclovir [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_a3ff2aa3-8920-40c2-82a4-3c78e8aedb01">12.3</a>)</span>].</p>
<p>Valacyclovir was noncarcinogenic in lifetime carcinogenicity bioassays at single daily doses (gavage) of valacyclovir giving plasma acyclovir concentrations equivalent to human levels in the mouse bioassay and 1.4 to 2.3 times human levels in the rat bioassay. There was no significant difference in the incidence of tumors between treated and control animals, nor did valacyclovir shorten the latency of tumors.</p>
<p>Valacyclovir was tested in 5 genetic toxicity assays. An Ames assay was negative in the absence or presence of metabolic activation. Also negative were an <span class="Italics">in vitro</span> cytogenetic study with human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> and a rat cytogenetic study.</p>
<p>In the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, valacyclovir was not mutagenic in the absence of metabolic activation. In the presence of metabolic activation (76% to 88% conversion to acyclovir), valacyclovir was mutagenic.</p>
<p>Valacyclovir was mutagenic in a mouse micronucleus assay.</p>
<p>Valacyclovir did not impair fertility or reproduction in rats at 6 times human plasma levels.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_6d02064c-bdd9-421f-862b-3665f00e2333"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ca7d5a22-38a1-4482-9a95-ca6627444d8d"></a><a name="section-13.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span>)</h2>
<p class="First">Two double-blind, placebo-controlled clinical trials were conducted in 1,856 healthy adults and adolescents (â‰¥ 12 years old) with a history of recurrent <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span>. Patients self-initiated therapy at the earliest symptoms and prior to any signs of a <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sore. The majority of patients initiated treatment within 2 hours of onset of symptoms. Patients were randomized to valacyclovir hydrochloride tablets 2 grams twice daily on Day 1 followed by placebo on Day 2, valacyclovir hydrochloride tablets 2 grams twice daily on Day 1 followed by 1 gram twice daily on Day 2, or placebo on Days 1 and 2.</p>
<p>The mean duration of <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sore episodes was about 1 day shorter in treated subjects as compared with placebo. The 2 day regimen did not offer additional benefit over the 1 day regimen.</p>
<p>No significant difference was observed between subjects receiving valacyclovir hydrochloride tablets or placebo in the prevention of progression of <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sore lesions beyond the papular stage.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_836c2332-e0f1-455c-91fa-f6e7b4264be2"></a><a name="section-13.2"></a><p></p>
<h2>14.2 <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span> Infections</h2>
<p class="First"><span class="Underline">Initial Episode:</span> Six hundred forty-three immunocompetent adults with first-episode <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> who presented within 72 hours of symptom onset were randomized in a double-blind trial to receive 10 days of valacyclovir hydrochloride tablets 1 gram twice daily (n = 323) or oral acyclovir 200 mg 5 times a day (n = 320). For both treatment groups: the median time to lesion healing was 9 days, the median time to cessation of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> was 5 days, the median time to cessation of viral shedding was 3 days.</p>
<p><span class="Underline">Recurrent Episodes:</span> Three double-blind trials (2 of them placebo-controlled) in immunocompetent adults with recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> were conducted. Patients self-initiated therapy within 24 hours of the first sign or symptom of a recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> episode.</p>
<p>In 1 study, patients were randomized to receive 5 days of treatment with either valacyclovir hydrochloride tablets 500 mg twice daily (n = 360) or placebo (n = 259). The median time to lesion healing was 4 days in the group receiving valacyclovir hydrochloride tablets 500 mg versus 6 days in the placebo group, and the median time to cessation of viral shedding in patients with at least 1 positive culture (42% of the overall study population) was 2 days in the group receiving valacyclovir hydrochloride tablets 500 mg versus 4 days in the placebo group. The median time to cessation of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> was 3 days in the group receiving valacyclovir hydrochloride tablets 500 mg versus 4 days in the placebo group. Results supporting efficacy were replicated in a second trial.</p>
<p>In a third study, patients were randomized to receive valacyclovir hydrochloride tablets 500 mg twice daily for 5 days (n = 398) or valacyclovir hydrochloride tablets 500 mg twice daily for 3 days (and matching placebo twice daily for 2 additional days) (n = 402). The median time to lesion healing was about 4Â½ days in both treatment groups. The median time to cessation of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> was about 3 days in both treatment groups.</p>
<p><span class="Underline">Suppressive Therapy:</span> Two clinical studies were conducted, one in immunocompetent adults and one in HIV-infected adults.</p>
<p>A double-blind, 12 month, placebo- and active-controlled study enrolled immunocompetent adults with a history of 6 or more recurrences per year. Outcomes for the overall study population are shown in <span class="Bold">Table 5</span>.</p>
<a name="id_5766b07e-4c87-4644-a415-5531b760c52c"></a><table width="0.000">
<caption><span>Table 5. Recurrence Rates in Immunocompetent Adults at 6 and 12 Months</span></caption>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Includes lost to follow-up, discontinuations due to adverse events, and consent withdrawn.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="left" rowspan="2" valign="top">Outcome</td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top">6 Months</td>
<td class="Botrule Lrule" align="center" colspan="3" valign="top">12 Months</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top">Valacyclovir hydrochloride tablets 1 gram once daily (n = 269)</td>
<td class="Botrule Rrule" align="center" valign="top">Oral acyclovir 400 mg twice daily (n = 267)</td>
<td class="Botrule Rrule" align="center" valign="top">Placebo (n = 134)</td>
<td class="Botrule Rrule" align="center" valign="top">Valacyclovir hydrochloride tablets 1 gram once daily (n = 269)</td>
<td class="Botrule Rrule" align="center" valign="top">Oral acyclovir 400 mg twice daily (n = 267)</td>
<td class="Botrule Lrule" align="center" valign="top">Placebo (n = 134)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Recurrence free</td>
<td class="Botrule Rrule" align="center" valign="top">55%</td>
<td class="Botrule Rrule" align="center" valign="top">54%</td>
<td class="Botrule Rrule" align="center" valign="top">7%</td>
<td class="Botrule Rrule" align="center" valign="top">34%</td>
<td class="Botrule Rrule" align="center" valign="top">34%</td>
<td class="Botrule Lrule" align="center" valign="top">4%</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Recurrences</td>
<td class="Botrule Rrule" align="center" valign="top">35%</td>
<td class="Botrule Rrule" align="center" valign="top">36%</td>
<td class="Botrule Rrule" align="center" valign="top">83%</td>
<td class="Botrule Rrule" align="center" valign="top">46%</td>
<td class="Botrule Rrule" align="center" valign="top">46%</td>
<td class="Botrule Lrule" align="center" valign="top">85%</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left" valign="top">Unknown<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="center" valign="top">10%</td>
<td class="Rrule" align="center" valign="top">10%</td>
<td class="Rrule" align="center" valign="top">10%</td>
<td class="Rrule" align="center" valign="top">19%</td>
<td class="Rrule" align="center" valign="top">19%</td>
<td class="Botrule" align="center" valign="top">10%</td>
</tr>
</tbody>
</table>
<p>Subjects with 9 or fewer recurrences per year showed comparable results with valacyclovir hydrochloride tablets 500 mg once daily.</p>
<p>In a second study, 293 HIV-infected adults on stable antiretroviral therapy with a history of 4 or more recurrences of ano-<span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> per year were randomized to receive either valacyclovir hydrochloride tablets 500 mg twice daily (n = 194) or matching placebo (n = 99) for 6 months. The median duration of recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> in enrolled subjects was 8 years, and the median number of recurrences in the year prior to enrollment was 5. Overall, the median prestudy HIV-1 RNA was 2.6 log<span class="Sub">10</span> copies/mL. Among patients who received valacyclovir hydrochloride tablets, the prestudy median CD4+ cell count was 336 cells/mm<span class="Sup">3</span>; 11% had &lt; 100 cells/mm<span class="Sup">3</span>, 16% had 100 to 199 cells/mm<span class="Sup">3</span>, 42% had 200 to 499 cells/mm<span class="Sup">3</span>, and 31% had â‰¥ 500 cells/mm<span class="Sup">3</span>. Outcomes for the overall study population are shown in <span class="Bold">Table 6</span>.</p>
<a name="id_2e2f0d3f-1acf-430e-aae9-fef9af507495"></a><table width="431">
<caption><span>Table 6. Recurrence Rates in HIV-Infected Adults at 6 Months</span></caption>
<col width="29.2%">
<col width="37.4%">
<col width="33.4%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Includes lost to follow-up, discontinuations due to adverse events, and consent withdrawn.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="center" valign="bottom">Outcome</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">Valacyclovir hydrochloride tablets 500 mg twice daily</p>
<p>(n = 194)</p>
</td>
<td class="Botrule Lrule" align="center" valign="bottom">
<p class="First">Placebo</p>
<p>(n = 99)</p>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Recurrence free</td>
<td class="Botrule Rrule" align="center" valign="middle">65%</td>
<td class="Botrule Lrule" align="center" valign="middle">26%</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Recurrences</td>
<td class="Botrule Rrule" align="center" valign="middle">17%</td>
<td class="Botrule Lrule" align="center" valign="middle">57%</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left" valign="top">Unknown<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a>
</td>
<td class="Rrule" align="center" valign="middle">18%</td>
<td class="Botrule" align="center" valign="middle">17%</td>
</tr>
</tbody>
</table>
<p><span class="Underline">Reduction of Transmission of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span>:</span> A double-blind, placebo-controlled study to assess transmission of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> was conducted in 1,484 monogamous, heterosexual, immunocompetent adult couples. The couples were discordant for HSV-2 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. The source partner had a history of 9 or fewer <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> episodes per year. Both partners were counseled on safer sex practices and were advised to use condoms throughout the study period. Source partners were randomized to treatment with either valacyclovir hydrochloride tablets 500 mg once daily or placebo once daily for 8 months. The primary efficacy endpoint was symptomatic acquisition of HSV-2 in susceptible partners. Overall HSV-2 acquisition was defined as symptomatic HSV-2 acquisition and/or HSV-2 seroconversion in susceptible partners. The efficacy results are summarized in <span class="Bold">Table 7</span>.</p>
<a name="id_d9009662-badf-4db3-9419-d6036f130f98"></a><table width="431">
<caption><span>Table 7. Percentage of Susceptible Partners Who Acquired HSV-2 Defined by the Primary and Selected Secondary Endpoints</span></caption>
<col width="40.1%">
<col width="34.6%">
<col width="25.3%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Results show reductions in risk of 75% (symptomatic HSV-2 acquisition), 50% (HSV-2 seroconversion), and 48% (overall HSV-2 acquisition) with valacyclovir hydrochloride tablets versus placebo. Individual results may vary based on consistency of safer sex practices.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="center" valign="bottom">Endpoint</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Valacyclovir Hydrochloride Tablets<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a></p>
<p>(n = 743)</p>
</td>
<td class="Botrule Lrule" align="center" valign="top">
<p class="First">Placebo</p>
<p>(n = 741)</p>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Symptomatic HSV-2 acquisition</td>
<td class="Botrule Rrule" align="center" valign="middle">4 (0.5%)</td>
<td class="Botrule Lrule" align="center" valign="middle">16 (2.2%)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">HSV-2 seroconversion</td>
<td class="Botrule Rrule" align="center" valign="middle">12 (1.6%)</td>
<td class="Botrule Lrule" align="center" valign="middle">24 (3.2%)</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left" valign="top">Overall HSV-2 acquisition</td>
<td class="Rrule" align="center" valign="middle">14 (1.9%)</td>
<td class="Botrule" align="center" valign="middle">27 (3.6%)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_15302c2f-0efb-4d7c-8adc-ef8fdf92db34"></a><a name="section-13.3"></a><p></p>
<h2>14.3 <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span></h2>
<p class="First">Two randomized double-blind clinical trials in immunocompetent adults with localized <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> were conducted. Valacyclovir hydrochloride tablets were compared with placebo in patients less than 50 years of age, and with oral acyclovir in patients greater than 50 years of age. All patients were treated within 72 hours of appearance of zoster <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. In patients less than 50 years of age, the median time to cessation of new lesion formation was 2 days for those treated with valacyclovir hydrochloride tablets compared with 3 days for those treated with placebo. In patients greater than 50 years of age, the median time to cessation of new lesions was 3 days in patients treated with either valacyclovir hydrochloride tablets or oral acyclovir. In patients less than 50 years of age, no difference was found with respect to the duration of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> after healing (post-herpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>) between the recipients of valacyclovir hydrochloride tablets and placebo. In patients greater than 50 years of age, among the 83% who reported <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> after healing (post-herpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>), the median duration of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> after healing [95% confidence interval] in days was: 40 [31, 51], 43 [36, 55], and 59 [41, 77] for 7 day valacyclovir hydrochloride tablets, 14 day valacyclovir hydrochloride tablets, and 7 day oral acyclovir, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c5717931-afec-457b-a3e5-e0df9dca12ee"></a><a name="section-13.4"></a><p></p>
<h2>14.4 <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span></h2>
<p class="First">The use of valacyclovir hydrochloride tablets for treatment of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> in pediatric patients 2 to &lt; 18 years of age is based on single-dose pharmacokinetic and multiple-dose safety data from an open-label trial with valacyclovir and supported by safety and extrapolated efficacy data from 3 randomized, double-blind, placebo-controlled trials evaluating oral acyclovir in pediatric patients. </p>
<p>The single-dose pharmacokinetic and multiple-dose safety study enrolled 27 pediatric patients 1 to &lt; 12 years of age with clinically suspected VZV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Each subject was dosed with valacyclovir oral suspension, 20 mg/kg 3 times daily for 5 days. Acyclovir systemic exposures in pediatric patients following valacyclovir oral suspension were compared with historical acyclovir systemic exposures in immunocompetent adults receiving the solid oral dosage form of valacyclovir or acyclovir for the treatment of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>. The mean projected daily acyclovir exposures in pediatric patients across all age-groups (1 to &lt; 12 years of age) were lower (C<span class="Sub">max</span>: â†“13%, AUC: â†“30%) than the mean daily historical exposures in adults receiving valacyclovir 1 gram 3 times daily, but were higher (daily AUC: â†‘50%) than the mean daily historical exposures in adults receiving acyclovir 800 mg 5 times daily. The projected daily exposures in pediatric patients were greater (daily AUC approximately 100% greater) than the exposures seen in immunocompetent pediatric patients receiving acyclovir 20 mg/kg 4 times daily for the treatment of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>. Based on the pharmacokinetic and safety data from this study and the safety and extrapolated efficacy data from the acyclovir studies, oral valacyclovir 20 mg/kg 3 times a day for 5 days (not to exceed 1 gram 3 times daily) is recommended for the treatment of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> in pediatric patients 2 to &lt; 18 years of age. Because the efficacy and safety of acyclovir for the treatment of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> in children &lt; 2 years of age have not been established, efficacy data cannot be extrapolated to support valacyclovir treatment in children &lt; 2 years of age with <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>. Valacyclovir is also not recommended for the treatment of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> in children because safety data up to 7 daysâ€™ duration are not available [<span class="Italics">see Use in Specific Populations (<a href="#i4i_pediatric_use_id_adce7f29-896b-4ad6-ac38-1fdc092b5bad">8.4</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_67360ca9-a82a-4b2e-85fc-7aebe20cbe07"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Valacyclovir hydrochloride tablets are available as follows:</p>
<p>500 mg: blue, film-coated, capsule-shaped tablets, debossed with "93" on one side and "7258" on the other.</p>
<p>1 gram: blue, film-coated, capsule-shaped tablets, partially scored on both sides and debossed with "93" on one side and "7259" on the other. Available in bottles of 30 NDC 42291-889-30.</p>
<p><span class="Bold">Storage:</span></p>
<p>Store at 20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled Room Temperature].</p>
<p>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_1cb8fef5-f341-402e-be89-eec4b518251e"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-Approved Patient Labeling.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a1f9038f-2e12-441b-aa34-4b875463148d"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Importance of Adequate Hydration</h2>
<p class="First">Patients should be advised to maintain adequate hydration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d1b67d89-b976-40b6-9e1f-5410bc3bff1e"></a><a name="section-15.2"></a><p></p>
<h2>17.2 <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold Sores</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Herpes Labialis</span>)</h2>
<p class="First">Patients should be advised to initiate treatment at the earliest symptom of a <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sore (e.g., <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, or burning). There are no data on the effectiveness of treatment initiated after the development of clinical signs of a <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sore (e.g., <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papule</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicle</span>, or <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>). Patients should be instructed that treatment for <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> should not exceed 1 day (2 doses) and that their doses should be taken about 12 hours apart. Patients should be informed that valacyclovir hydrochloride tablets are not a cure for <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7ef40c03-a7ee-49ba-87e5-78c85f95859e"></a><a name="section-15.3"></a><p></p>
<h2>17.3 <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital Herpes</span></h2>
<p class="First">Patients should be informed that valacyclovir hydrochloride tablets are not a cure for <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>. Because <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> is a <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted disease</span>, patients should avoid contact with lesions or intercourse when lesions and/or symptoms are present to avoid infecting partners. <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital herpes</span> is frequently transmitted in the absence of symptoms through asymptomatic viral shedding. Therefore, patients should be counseled to use safer sex practices in combination with suppressive therapy with valacyclovir hydrochloride tablets. Sex partners of infected persons should be advised that they might be infected even if they have no symptoms. Type-specific serologic testing of asymptomatic partners of persons with <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> can determine whether risk for HSV-2 acquisition exists.</p>
<p>Valacyclovir hydrochloride tablets have not been shown to reduce transmission of sexually transmitted <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> other than HSV-2.</p>
<p>If medical management of a <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> recurrence is indicated, patients should be advised to initiate therapy at the first sign or symptom of an episode.</p>
<p>There are no data on the effectiveness of treatment initiated more than 72 hours after the onset of signs and symptoms of a first episode of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> or more than 24 hours after the onset of signs and symptoms of a recurrent episode.</p>
<p>There are no data on the safety or effectiveness of chronic suppressive therapy of more than 1 year's duration in otherwise healthy patients. There are no data on the safety or effectiveness of chronic suppressive therapy of more than 6 months' duration in HIV-infected patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_933d73e2-ba01-4224-804b-853cd4a36f23"></a><a name="section-15.4"></a><p></p>
<h2>17.4 <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span></h2>
<p class="First">There are no data on treatment initiated more than 72 hours after onset of the zoster <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. Patients should be advised to initiate treatment as soon as possible after a diagnosis of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_617a0d5d-2fb3-4130-a15a-d4309bea3ac9"></a><a name="section-15.5"></a><p></p>
<h2>17.5 <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span></h2>
<p class="First">Patients should be advised to initiate treatment at the earliest sign or symptom of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>.</p>
<p>Manufactured For:</p>
<p><span class="Bold">AvKARE, Inc.</span></p>
<p>Pulaski, TN 38478</p>
<p>Mfg. Rev. C 02/12 <br>AV 02/13 (P)</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_75b19a34-f031-41a1-8966-62d32b991393"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">PATIENT INFORMATION</span></p>
<p><span class="Bold">VALACYCLOVIR HYDROCHLORIDE TABLETS</span></p>
<p>Read the Patient Information that comes with valacyclovir hydrochloride tablets before you start using them and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. Ask your healthcare provider or pharmacist if you have questions.</p>
<p><span class="Bold"><span class="Underline">What are valacyclovir hydrochloride tablets?</span></span></p>
<p>Valacyclovir hydrochloride tablets are a prescription antiviral medicine. Valacyclovir hydrochloride tablets lower the ability of herpes viruses to multiply in your body.</p>
<p>Valacyclovir hydrochloride tablets are used in adults:</p>
<ul>
<li>to treat <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> (also called <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">fever blisters</span> or <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span>)</li>
<li>to treat <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">shingles</span> (also called <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>)</li>
<li>to treat or control <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> outbreaks in adults with normal immune systems</li>
<li>to control <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> outbreaks in adults infected with the human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV) with CD4+ cell count greater than 100 cells/mm<span class="Sup">3</span>
</li>
<li>with safer sex practices to lower the chances of spreading <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> to others. Even with safer sex practices, it is still possible to spread <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>.</li>
</ul>
<p>Valacyclovir hydrochloride tablets used daily with the following safer sex practices can lower the chances of passing <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> to your partner.</p>
<ul>
<li><span class="Bold">Do not have sexual contact with your partner when you have any symptom or outbreak of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>.</span></li>
<li>
<span class="Bold">Use a condom</span> made of latex or polyurethane whenever you have sexual contact.</li>
</ul>
<p>Valacyclovir hydrochloride tablets are used in children:</p>
<ul>
<li>to treat <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> (for children â‰¥ 12 years of age)</li>
<li>to treat <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> (for children 2 to &lt; 18 years of age). </li>
</ul>
<p><span class="Bold">Valacyclovir hydrochloride tablets do not cure <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes infections</span></span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span>, <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">shingles</span>, or <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>).</p>
<p>The efficacy of valacyclovir hydrochloride tablets has not been studied in children who have not reached puberty.</p>
<p><span class="Bold"><span class="Underline">What are <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span>, <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">shingles</span>, and <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>?</span></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">Cold sores</span></span> are caused by a herpes virus that may be spread by kissing or other physical contact with the infected area of the skin. They are small, painful <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> that you get in or around your mouth. It is not known if valacyclovir hydrochloride tablets can stop the spread of <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> to others.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span> </span>is caused by a herpes virus. It causes an <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> of multiple small, red bumps that look like pimples or insect bites usually appearing first on the abdomen or back and face. It can spread to almost everywhere else on the body and may be accompanied by flu-like symptoms.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Shingles</span></span> is caused by the same herpes virus that causes <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>. It causes small, painful <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> that happen on your skin. <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Shingles</span> occurs in people who have already had <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>. <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Shingles</span> can be spread to people who have not had <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> or the <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> vaccine by contact with the infected areas of the skin. It is not known if valacyclovir hydrochloride tablets can stop the spread of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">shingles</span> to others.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">Genital herpes</span></span> is a <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted disease</span>. It causes small, painful <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> on your genital area. You can spread <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> to others, even when you have no symptoms. If you are sexually active, you can still pass herpes to your partner, even if you are taking valacyclovir hydrochloride tablets. Valacyclovir hydrochloride tablets, taken every day as prescribed and used with the following <span class="Bold">safer sex practices</span>, can lower the chances of passing <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> to your partner.</p>
<ul>
<li>Do not have sexual contact with your partner when you have any symptom or outbreak of <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>.</li>
<li>Use a condom made of latex or polyurethane whenever you have sexual contact.</li>
</ul>
<p>Ask your healthcare provider for more information about safer sex practices.</p>
<p><span class="Bold"><span class="Underline">Who should not take valacyclovir hydrochloride tablets?</span></span></p>
<p><span class="Bold">Do not take valacyclovir hydrochloride tablets</span> if you are allergic to any of their ingredients or to acyclovir. The active ingredient is valacyclovir. See the end of this leaflet for a complete list of ingredients in valacyclovir hydrochloride tablets.</p>
<p><span class="Bold"><span class="Underline">Before taking valacyclovir hydrochloride tablets, tell your healthcare provider</span>:</span></p>
<p><span class="Bold">About all your medical conditions,</span> including:</p>
<ul>
<li>
<span class="Bold">if you have had a bone marrow transplant or kidney transplant, or if you have advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span> or "AIDS".</span> Patients with these conditions may have a higher chance for getting a <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood disorder</span> called <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">thrombotic thrombocytopenic purpura</span>/<span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">hemolytic uremic syndrome</span> (TTP/HUS). TTP/HUS can result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</li>
<li>
<span class="Bold">if you have kidney problems.</span> Patients with kidney problems may have a higher chance for getting side effects or more kidney problems with valacyclovir hydrochloride tablets. Your healthcare provider may give you a lower dose of valacyclovir hydrochloride tablets.</li>
<li>
<span class="Bold">if you are 65 years of age or older.</span> Elderly patients have a higher chance of certain side effects. Also, elderly patients are more likely to have kidney problems. Your healthcare provider may give you a lower dose of valacyclovir hydrochloride tablets.</li>
<li>
<span class="Bold">if you are pregnant or planning to become pregnant.</span> Talk with your healthcare provider about the risks and benefits of taking prescription drugs (including valacyclovir hydrochloride tablets) during pregnancy.</li>
<li>
<span class="Bold">if you are breastfeeding.</span> Valacyclovir hydrochloride may pass into your milk and it may harm your baby. Talk with your healthcare provider about the best way to feed your baby if you are taking valacyclovir hydrochloride tablets.</li>
<li>
<span class="Bold">about all the medicines you take,</span> including prescription and non-prescription medicines, vitamins, and herbal supplements. Valacyclovir hydrochloride tablets may affect other medicines, and other medicines may affect valacyclovir hydrochloride tablets. It is a good idea to keep a complete list of all the medicines you take. Show this list to your healthcare provider and pharmacist any time you get a new medicine.</li>
</ul>
<p><span class="Underline"><span class="Bold">How should I take valacyclovir hydrochloride tablets?</span></span></p>
<p>Take valacyclovir hydrochloride tablets exactly as prescribed by your healthcare provider. Your dose of valacyclovir hydrochloride tablets and length of treatment will depend on the type of <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes infection</span> that you have and any other medical problems that you have.</p>
<ul>
<li>Do not stop valacyclovir hydrochloride tablets or change your treatment without talking to your healthcare provider.</li>
<li>Valacyclovir hydrochloride tablets can be taken with or without food.</li>
<li>If you are taking valacyclovir hydrochloride tablets to treat <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span>, <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">shingles</span>, or <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>, you should start treatment as soon as possible after your symptoms start. Valacyclovir hydrochloride tablets may not help you if you start treatment too late.</li>
<li>If you miss a dose of valacyclovir hydrochloride tablets, take it as soon as you remember and then take your next dose at its regular time. However, if it is almost time for your next dose, do not take the missed dose. Wait and take the next dose at the regular time.</li>
<li>Do not take more than the prescribed number of valacyclovir hydrochloride tablets each day. Call your healthcare provider right away if you take too many valacyclovir hydrochloride tablets.</li>
</ul>
<p><span class="Bold"><span class="Underline">What are the possible side effects of valacyclovir hydrochloride tablets?</span></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Kidney failure</span> and nervous system problems are not common, but can be serious in some patients taking valacyclovir hydrochloride tablets.</span> Nervous system problems include <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span>, unsteady movement, shaky movements, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, speech problems, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> (seeing or hearing things that are really not there), <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Kidney failure</span> and nervous system problems have happened in patients who already have kidney disease and in elderly patients whose kidneys do not work well due to age. <span class="Bold">Always tell your healthcare provider if you have kidney problems before taking valacyclovir hydrochloride tablets. Call your doctor right away if you get a nervous system problem while you are taking valacyclovir hydrochloride tablets.</span></p>
<p>Common side effects of valacyclovir hydrochloride tablets in adults include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. Side effects in HIV-infected adults include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. These side effects usually are mild and do not cause patients to stop taking valacyclovir hydrochloride tablets.</p>
<p>Other less common side effects in adults include painful periods in women, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, low blood cell counts, and changes in tests that measure how well the liver and kidneys work.</p>
<p>The most common side effect seen in children &lt; 18 years of age was <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<p><span class="Bold">Talk to your healthcare provider if you develop any side effects that concern you.</span></p>
<p>These are not all the side effects of valacyclovir hydrochloride tablets. For more information ask your healthcare provider or pharmacist.</p>
<p><span class="Bold"><span class="Underline">How should I store valacyclovir hydrochloride tablets?</span></span></p>
<ul>
<li>Store valacyclovir hydrochloride tablets at room temperature, 20Â° to 25Â°C (68Â° to 77Â°F).</li>
<li>Store valacyclovir hydrochloride suspension between 2Â° to 8Â°C (36Â° to 46Â°F) in a refrigerator. Discard after 28 days. </li>
<li>Keep valacyclovir hydrochloride tablets in a tightly closed container.</li>
<li>Do not keep medicine that is out of date or that you no longer need.</li>
<li>Keep valacyclovir hydrochloride tablets and all medicines out of the reach of children.</li>
</ul>
<p><span class="Bold"><span class="Underline">General information about valacyclovir hydrochloride tablets</span></span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use valacyclovir hydrochloride tablets for a condition for which they were not prescribed. Do not give valacyclovir hydrochloride tablets to other people, even if they have the same symptoms you have. They may harm them.</p>
<p>This leaflet summarizes the most important information about valacyclovir hydrochloride tablets. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about valacyclovir hydrochloride tablets that is written for health professionals. More information is available by calling 1-888-838-2872, MEDICAL AFFAIRS.</p>
<p><span class="Bold"><span class="Underline">What are the ingredients in valacyclovir hydrochloride tablets?</span></span></p>
<p><span class="Bold">Active Ingredient:</span> valacyclovir hydrochloride</p>
<p><span class="Bold">Inactive Ingredients:</span> cellulose, croscarmellose sodium, FD&amp;C blue #2, hypromellose, maize starch, polyethylene glycol, polysorbate 80, sodium stearyl fumarate, and titanium dioxide.</p>
<p>Manufactured For:</p>
<p><span class="Bold">AvKARE, Inc.</span></p>
<p>Pulaski, TN 38478</p>
<p>Mfg. Rev. A 03/12 <br>AV 02/13 (P)</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_2e14c008-4605-e29a-1d67-033758d79dfc"></a><a name="section-17"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">AvKARE<br><br>NDC</span> 42291-889-30<br><br><span class="Bold">Valacyclovir Hydrochloride Tablets</span></p>
<p><span class="Bold">1 g*<br><br></span>30 TabletsÂ Â Â Â Â Â Â Â  Rx Only</p>
<p><span class="Bold">PHARMACIST: PLEASE DISPENSE WITH ATTACHED PATIENT INFORMATION LEAFLET.<br><br></span>Do not use if safety seal under cap is broken or missing.<br><br><span class="Bold">*Each film-coated tablet contains </span>valacyclovir hydrochloride equivalent to 1 g valacyclovir.<br><br><span class="Bold">Usual Dosage: </span>See package insert for full prescribing information.</p>
<p><span class="Bold">Store</span> at 20o to 25<span class="Sup">o</span>C (68<span class="Sup">o</span> to 77<span class="Sup">o</span>F) [See USP Controlled Room Temperature].<br><br>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).<br><br><span class="Bold">KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</span></p>
<p>Manufactured for:<br><span class="Bold">AvKARE, Inc.<br></span>Pulaski, TN 38478<br><br>Mfg. Iss. 12/09<br>AV 05/13 (P)<br></p>
<p><span class="Bold">N</span>3Â Â  42291 88930Â Â  9</p>
<div class="Figure"><img alt="label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c31fdda3-217c-c452-eb9b-aba705456aa1&amp;name=Screen%20Shot%202013-07-15%20at%2010.10.32%20AM.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VALACYCLOVIR HYDROCHLORIDE Â 		
					</strong><br><span class="contentTableReg">valacyclovir hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42291-889(NDC:0093-7259)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>VALACYCLOVIR HYDROCHLORIDE</strong> (ACYCLOVIR) </td>
<td class="formItem">VALACYCLOVIR</td>
<td class="formItem">1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POWDERED CELLULOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STEARYL FUMARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">23mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">93;7259</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42291-889-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077655</td>
<td class="formItem">07/11/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>AvKARE, Inc.
							(796560394)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f8ac9647-7644-6520-5147-dc87e2db7b7d</div>
<div>Set id: c31fdda3-217c-c452-eb9b-aba705456aa1</div>
<div>Version: 2</div>
<div>Effective Time: 20130711</div>
</div>
</div>Â <div class="DistributorName">AvKARE, Inc.</div></p>
</body></html>
